Innostar appoints Dr. Sean Xiaochun Chen as CSO

SHANGHAI, 5 November 2024 - Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar) has officially announced the appointment of Dr. Sean Xiaochun Chen as Chief Scientific Officer (CSO) reporting to Dr. Yan Chang, President of InnoStar. Dr. Chen will lead and drive InnoStar's technological development and international market expansion in the field of non-clinical toxicology, contributing to InnoStar's growth on a global scale.

Dr. Chen is a senior pharmacology and toxicology expert with over 20 years of experience in new drug discovery and development research. He served as a senior non-clinical review expert at the US Food and Drug Administration (FDA), working for over 8 years in the FDA's Center for New Drug Evaluation (CDER/OND) and Center for Biological Products Evaluation (CBER/OTP). During this time, Dr. Chen was responsible for the oversight of clinical research and marketing applications for small molecules, macromolecules, cell therapy, gene therapy, live organisms, and combination products, and participated in the approval of hundreds of Investigational New Drug applications and more than ten NDA/BLA marketing applications. Dr. Chen has demonstrated outstanding leadership and innovation during his tenure at the FDA. He not only provides valuable advice and guidance to companies on experimental design, data interpretation and product development strategies, but also provides pioneering regulatory recommendations and solutions for highly complex innovative products where precedents and guidance are lacking. In addition, Dr. Chen serves on several FDA subcommittees, consults on internal reviews, and participates in the drafting and development of several industry guidelines.

Dr. Chen received his Ph.D. in biomedical engineering from Zhejiang University. After completing his postdoctoral research at the Johns Hopkins University School of Medicine, he served as an Assistant Professor at the Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, focusing on the discovery and development of innovative drugs. His research team has discovered several novel anti-leukemia and anti-infective drug candidates, one of which is currently in non-clinical development for the treatment of leukemia.

Dr. Chen: I'm incredibly grateful to InnoStar for trusting me and giving me this opportunity. It's a real honor to be part of such a professional team. I'm looking forward to working with my InnoStar colleagues on this platform to push the boundaries of scientific research and innovation in our society. I'm also committed to driving InnoStar's international expansion and strategic partnerships, accelerating research translation and project growth, and delivering first-class, efficient services to our clients. I'm excited about the future and hope that InnoStar will grow with me.

Dr. Chang Yan, President of InnoStar, extended a warm welcome to Dr. Chen Xiaochun and expressed confidence that his appointment will infuse the company with new vigor and momentum. InnoStar will continue to adhere to its core vision of 'Specializing in R&D Services and Empowering the Healthcare Industry' and is committed to providing customers with enhanced quality services and more efficient solutions, while also promoting the flourishing global biopharmaceutical industry.